Studying the Effectiveness of Ribavirin® in the Experimental Form of Severe Acute Respiratory Syndrome
- 25 May 2020
- journal article
- Published by Publishing House OKI in Antibiotics and Chemotherapy
- Vol. 65 (1-2), 21-26
- https://doi.org/10.37489/0235-2990-2020-65-1-2-21-26
Abstract
The effectiveness of Ribavirin® was evaluated by the certainty of disease severity reduction and the coefficient of therapeutic action of drugs at the peak of the pathological process calculated by the following indicators: accumulation of the virus in the lungs, lung damage degree reduction, reduction observed in the severity of changes in the quantitative and qualitative characteristics of white blood, as well as the severity of changes in biochemical blood parameters. Ribavirin® is most effective when used according to the emergency prevention regimen at a dose of 20 mg/kg (therapeutic action coefficient — 70%); at a dose of 40 mg/kg according to the therapeutic and prophylactic regimen (therapeutic action coefficient — 60%). Increasing the dose of Ribavirin® did not contribute to the therapeutic effectiveness of the drug.Keywords
This publication has 6 references indexed in Scilit:
- Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral DrugsEmerging Infectious Diseases, 2004
- Interferon-β 1a and SARS Coronavirus ReplicationEmerging Infectious Diseases, 2004
- Inflammatory Cytokine Profile in Children With Severe Acute Respiratory SyndromePEDIATRICS, 2004
- Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR ChinaJournal of Medical Microbiology, 2003
- Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto AreaJAMA, 2003
- A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong KongThe New England Journal of Medicine, 2003